This Article Full Text Full Text (PDF) All Versions of this Article: 36/10/2170    most recent 01.STR.0000179044.37760.9dv1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Gamboa, A. Articles by Biaggioni, I. Search for Related Content PubMed PubMed Citation Articles by Gamboa, A. Articles by Biaggioni, I. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Hazardous Substances DB ACETYLSALICYLIC ACID NITRIC OXIDE Related Collections Cardiovascular Pharmacology Antiplatelets Endothelium/vascular type/nitric oxide

(Stroke. 2005;36:2170.)
© 2005 American Heart Association, Inc.

Original Contributions

Role of Adenosine and Nitric Oxide on the Mechanisms of Action of Dipyridamole

Alfredo Gamboa, MD; Robert Abraham, MD; Andre Diedrich, MD; Cyndya Shibao, MD; Sachin Y. Paranjape, BS; Ginnie Farley Italo Biaggioni, MD

From the Division of Clinical Pharmacology (A.G., A.D., C.S., S.Y.P., G.F., I.B.), Department of Medicine (A.G., R.A., A.D., C.S., S.Y.P., G.F., I.B.) and Pharmacology (I.B.), and the Autonomic Dysfunction Center, Vanderbilt University School of Medicine, Nashville, Tenn.

Correspondence to Italo Biaggioni, MD, 1500 21st Ave S, Suite 3500, Clinical Trials Center, Vanderbilt University, Nashville, TN 37212. E-mail italo.biaggioni{at}vanderbilt.edu

Background and Purpose— The combination of dipyridamole and aspirin has been shown to be more effective than aspirin alone in the secondary prevention of stroke. Dipyridamole may act by inhibiting adenosine uptake, thus potentiating its actions. Dipyridamole also inhibits cGMP-specific phosphodiesterases (PDE) and, through this mechanism, could potentiate cGMP-mediated actions of nitric oxide.

Methods— To define the mechanism of action of dipyridamole, we studied the local vascular effects of adenosine, acetylcholine (NO-mediated dilation), and nitroprusside (cGMP-mediated dilation) in a double-blind study after treatment with dipyridamole/aspirin (200 mg dipyridamole/25 mg aspirin twice a day) or aspirin control for 7 days in 6 normal volunteers. Vasodilators were administered into the brachial artery in the nondominant arm in random order and forearm blood flow (FBF) was measured by venous occlusion plethysmography.

Results— Adenosine at a dosage of 125 µg/min increased FBF from 4.6±0.9 to 29.4±5.3 (539% increase) with dipyridamole/aspirin and from 3.9±0.8 to 12±2.5 mL/100 mL forearm/min (208% increase) with aspirin alone (P=0.007). In contrast, dipyridamole/aspirin did not alter the response to acetylcholine or to nitroprusside. The magnitude of adenosine-induced vasodilation correlated with plasma dipyridamole concentrations (r²=0.6); no correlation was observed with acetylcholine- or nitroprusside-induced vasodilation. Similar potentiation of adenosine, but not acetylcholine or nitroprusside, was observed in 7 additional subjects when adenosine, acetylcholine, and nitroprusside were given in random order before and 2 hours after a single dose of dipyridamole/aspirin.

Conclusion— The effects of dipyridamole on resistance vessels are preferentially explained by potentiation of adenosine mechanisms rather than potentiation of nitric oxide or other cGMP-mediated actions.

Key Words: adenosine • aspirin • dipyridamole • endothelium • nitric oxide • regional blood flow

This article has been cited by other articles:

				H.-H. Kim and J. K. Liao Translational Therapeutics of Dipyridamole Arterioscler. Thromb. Vasc. Biol., March 1, 2008; 28(3): s39 - s42. [Abstract] [Full Text] [PDF]